Home>Topics>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals REGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Global Diabetic Retinopathy Market 2015 - Global Market Size, Trends, Development, and Forecasts to 2019

      Commentary

      Tue, 21 Apr 2015

      Americas - EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other Prominent Vendors - Abbott Laboratories Ltd

    2. CORRECTED-U.S. FDA again expands usage of Regeneron eye drug Eylea

      Headlines

      Wed, 25 Mar 2015

      March 25 (Reuters) - U.S. health regulators on Wednesday approved Regeneron Pharmaceuticals Inc's big-selling eye drug Eylea to treat diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in adults.

    3. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      anti-VEGF treatments that require monthly injections (Roche's RHHBY Lucentis) and bimonthly injections (Regeneron's REGN Eylea). We think the first DARPin molecule is likely to enter Phase III trials by 2016. Molecular Partners can earn as much

    4. From Barron’s, March 23, 2015 (Part 1)

      Commentary

      Sat, 21 Mar 2015

      NFLX, DIS, NVS, M, Tencents/700.hk/TCEHY, FCA.it/FCAU, GILD, CVS, TJX, RYA.ir/RYAAY, GOOGL, UA, HDB, REGN , SBUX, FDX, SoftBank/9984.ja/SFTBY, ICE, ABT, Fast Retailing/9983.ja/FRCOY, Lenovo/992.hk/LNVGY, FB

    5. Complexities of Eye Care Drive Strong Moats

      Headlines

      Fri, 6 Mar 2015

      for wet age-related macular degeneration and diabetic macular degeneration have been wildly successful, with Regeneron 's REGN and Bayer 's BAYRY Eylea and Novartis ' NVS and Roche 's RHHBY Lucentis both easily reaching blockbuster status. Other eye

    6. From Barron’s, January 5, 2015 (Part 1)

      Commentary

      Sat, 3 Jan 2015

      Holdings [ CPA ] is attractive for a rebound play. Strong large-cap performers with significant insider activity include KMI, REGN , RSG, VRX, CHTR, DVA, TWX . For the week , DJIA -1.22% , SP500 -1.46% , Nasdaq Comp -1.67% , Russell 2000

    7. A Biotech With a Growing Moat

      Video Reports

      Wed, 31 Dec 2014

      Stefan Quenneville: Regeneron ( REGN ) is a biotechnology company that we rate as having a narrow moat and a positive moat trend. We think its positive moat trend

      REGN found at 0:03

      Stefan Quenneville: Regeneron ( REGN ) is a biotechnology company that we rate as having a narrow moat and a positive moat trend. We think its positive moat
    8. REGN

      Commentary

      Tue, 25 Nov 2014

      Can anyone provide some insight on why they think this company would be a Great Investment? Thank you for the input!

    9. Sifting Through Fidelity's Large-Cap Medalists

      Headlines

      Thu, 3 Apr 2014

      Some of his biggest winners in recent years are shares he bought years ago when they were much smaller, including Regeneron REGN and Salesforce.com CRM. Wymer has beaten large-growth peers during his tenure, albeit with greater volatility. Wymer doesn

    10. From Barron’s, March 31, 2014 (Part 2)

      Commentary

      Sat, 29 Mar 2014

      relative to sectors such as IT that require lesser capex. Some highflyers sank last week, e.g. biotechs [ ALXN, CELG, GILD, REGN ] and other momentum favorites [ GMCR, FB, TWTR, P, YELP, NFLX, BIDU ]; fears of higher rates and weaker economy were

    « Prev12345Next »
    Content Partners